Please login to the form below

Not currently logged in
Email:
Password:

Merck & Co and Pfizer take aim at diabetes with trio of new drugs

File ertugliflozin-based products with EU and US regulators

Pfizer Merck & Co diabetes alliance

Merck & Co and Pfizer's four-year-old alliance in diabetes has reached fruition with the filing of three new products based on new SGLT2 inhibitor ertugliflozin.

The marketing applications – filed in the US and EU – cover ertugliflozin as a monotherapy, a fixed-dose combination of ertugliflozin and Januvia (sitagliptin), and a fixed-dose combination of the SGLT2 inhibitor and metformin.

Merck (known as MSD outside North America) and Pfizer have been working together on ertugliflozin's development since 2013, but are late to the SGLT2 inhibitor party as there are already three other drugs in the class on the market.

The first SGLT2 inhibitor to be approved in the US was Johnson & Johnson's Invokana (canagliflozin) in 2013, while in Europe it was AstraZeneca's Forxiga/Farxiga (dapagliflozin) the previous year.

These were joined in Lilly/Boehringer's Jardiance (empagliflozin) in 2014, along with several combinations in the intervening years.

With ertugliflozin reviews now ongoing at the FDA and EMA, the two partners are hopeful of approval by the end of the year, saying that the trio of ertugliflozin products will provide additional treatment options for type 2 diabetics.

Merck and Pfizer hope to close the gap with the leaders – and particularly fast-growing Jardiance - with a large-scale outcomes study for ertugliflozin to see if it can reduce cardiovascular death, nonfatal myocardial infarction or nonfatal stroke, and hospitalization for heart failure.

The 8,000-patient VERTIS CV trial is due to report in 2019. A tougher pricing and reimbursement environment means cardiovascular outcomes data has become increasingly important for diabetes drugs, which need more than data on controlling blood sugar to lift themselves above their rivals in an increasingly crowded market.

Lilly and Boehringer's EMPA-REG OUTCOME trial of Jardiance is a case in point, helping sales of the drug accelerate from a relatively low base last year and potentially adding $1.7bn to peak revenues for the drug, according to analysts at Evercore.

Meanwhile, J&J is scheduled to report outcomes data on Invokana later this year, while AZ and Boehringer's trial is due to generate results in 2019. Merck and Pfizer insist ertugliflozin and its combinations offer "best-in-class" profiles that will help them make inroads into the market, and analysts at Credit Suisse seem to be of the same mind.

In a report issued last year they predicted $1.3bn in sales for the portfolio in 2020. J&J's Invokana franchise brought in $1.4bn in sales last year, largely flat on the prior year, while AZ reported Forxiga sales of $832m (up 72%) and Jardiance rose 60% to $202m.

Article by
Phil Taylor

7th March 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....